Inhibition of the PI3K/AKT signaling pathway increases efficacy of doxorubicin and its derivative AD198 in bladder and oral cancers
Doctoral Dissertations
Part of the Medicine and Health Sciences Commons
Part of the Medicine and Health Sciences Commons